celecoxib has been researched along with thromboxane a2 in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bing, RJ; Johnson, PE; Kakar, NR; Vina, ER; Yamamoto, T | 1 |
| García Rodríguez, LA; Patrignani, P; Patrono, C | 1 |
| Gately, S; Li, WW | 1 |
| Fitzgerald, GA | 1 |
| Busse, R; Fleming, I; Kohlstedt, K | 1 |
| Bjorling, DE; Calamon-Dixon, JL; Jerde, TJ; Nakada, SY | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Guo, ZR | 1 |
| Dogné, JM; Hanson, J; Pratico, D; Supuran, C | 1 |
| Marwali, MR; Mehta, JL | 1 |
| Dahlén, SE; Kumlin, M; Låstbom, L; Ryrfeldt, A; Selg, E | 1 |
| Huang, YP; Liu, LJ; Wang, LX; Xie, YP; Zeng, HH | 1 |
| Anzellotti, P; Bertario, L; Bruno, A; Di Francesco, L; Dixon, DA; Dovizio, M; FitzGerald, GA; Lawson, JA; Maier, TJ; Patrignani, P; Ricciotti, E; Sala, P; Signoroni, S; Steinhilber, D; Tacconelli, S | 1 |
| Ahmed, SB; Beaudin, AE; Hanly, PJ; Nicholl, DD; Poulin, MJ; Pun, M; Slater, DM; Steinback, CD; Wynne-Edwards, KE; Yang, C | 1 |
| Bueno-Betí, C; García-Giménez, JL; Hermenegildo, C; Ibañez-Cabellos, JS; Novella, S; Pallardó, FV; Pérez-Cremades, D | 1 |
5 review(s) available for celecoxib and thromboxane a2
| Article | Year |
|---|---|
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dinoprostone; Epoprostenol; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Substrate Specificity; Sulfonamides; Sulfones; Thromboembolism; Thromboxane A2; Treatment Outcome | 2001 |
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epidermal Growth Factor; Epoprostenol; Humans; Interleukin-12; Isoenzymes; Lactones; Matrix Metalloproteinases; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Thromboxane A2; Vascular Endothelial Growth Factor A | 2004 |
[Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Thromboxane A2 | 2005 |
Coxibs and cardiovascular side-effects: from light to shadow.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
1 trial(s) available for celecoxib and thromboxane a2
| Article | Year |
|---|---|
Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea.
Topics: Adult; Blood Pressure; Celecoxib; Cerebrovascular Circulation; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprost; Dinoprostone; Double-Blind Method; Epoprostenol; Female; Heart Rate; Humans; Hypoxia; Indomethacin; Male; Middle Aged; Pyrazoles; Sleep Apnea, Obstructive; Sulfonamides; Thromboxane A2 | 2014 |
9 other study(ies) available for celecoxib and thromboxane a2
| Article | Year |
|---|---|
Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Heart; Isoenzymes; Male; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Sulfonamides; Thromboxane A2 | 2001 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; Amino Acid Substitution; Angiotensin-Converting Enzyme Inhibitors; Animals; Anthracenes; Aorta; Binding, Competitive; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Humans; JNK Mitogen-Activated Protein Kinases; Lung; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation, Missense; Oligodeoxyribonucleotides; Peptidyl-Dipeptidase A; Phosphorylation; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Prostaglandins I; Protein Processing, Post-Translational; Pyrazoles; Ramipril; Recombinant Fusion Proteins; Signal Transduction; Sulfonamides; Sus scrofa; Thromboxane A2; Transcription Factor AP-1; Transcription, Genetic; Transfection; Umbilical Veins | 2005 |
Celecoxib inhibits ureteral contractility and prostanoid release.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase Inhibitors; Depression, Chemical; Dimethyl Sulfoxide; Dinoprost; Dinoprostone; Gas Chromatography-Mass Spectrometry; Humans; Indomethacin; Muscle Contraction; Nitrobenzenes; Prostaglandin Antagonists; Prostaglandin D2; Prostaglandins; Pyrazoles; Secretory Rate; Sulfonamides; Sus scrofa; Thromboxane A2; Tumor Necrosis Factor-alpha; Ureter; Ureteral Obstruction | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Effects of selective and non-selective COX inhibitors on antigen-induced release of prostanoid mediators and bronchoconstriction in the isolated perfused and ventilated guinea pig lung.
Topics: Animals; Bronchoconstriction; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Flurbiprofen; Guinea Pigs; Humans; Leukotrienes; Lung; Male; Ovalbumin; Piperazines; Prostaglandins; Pyrazoles; Sulfonamides; Thiazoles; Thromboxane A2; Thromboxane B2 | 2008 |
[Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats].
Topics: Animals; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Epoprostenol; Hypercapnia; Hypertension, Pulmonary; Hypoxia; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Thromboxane A2 | 2011 |
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Female; HT29 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Neovascularization, Physiologic; Prostaglandins; Pyrazoles; Sulfonamides; Thromboxane A2; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Extracellular histones disarrange vasoactive mediators release through a COX-NOS interaction in human endothelial cells.
Topics: Celecoxib; Cyclic N-Oxides; Cyclooxygenase 1; Cyclooxygenase 2; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Epoprostenol; Gene Expression Regulation; Histones; Human Umbilical Vein Endothelial Cells; Humans; Intramolecular Oxidoreductases; Nitric Oxide; Nitric Oxide Synthase Type III; Primary Cell Culture; RNA, Messenger; Signal Transduction; Spin Labels; Superoxides; Thromboxane A2; Thromboxane-A Synthase | 2017 |